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Introduction
BRCA1 (breast cancer susceptibility gene 1) and BRCA2 are 
important ‘caretaker’ tumour suppressor genes involved in many 
cellular processes. In particular, the products of both genes are central 
to the mechanisms of DNA repair and transcriptional regulation in 
response to DNA damage [1]. BRCA1 and BRCA2 are critical in the 
repair of DNA double strand breaks (DSB) which are the predominant 
form of cellular injury caused by exposure to ionising radiation [2]. 
Human cells utilise two principal mechanisms to repair DNA DSB. In 
non-cycling and cells in early G1, non homologous end joining (NHEJ) 
is predominant. Here DNA DSB are ligated together in an error prone 
manner and central to this process is the DNA dependent protein 
kinase (DNA-PK) and its associated proteins Ku70 and Ku80 together 
with the end processing enzyme artemis. Finally ligation of broken 
ends is mediated by the XRCC4-ligase IV complex [3].
Alternatively, in cycling cells in the later phases of the cell cycle, 
DSB repair is mediated by the process of homologous recombination 
(HR), whereby the repair of the DSB is achieved through exchange of 
genetic material from the homologous chromosome or sister chromatid 
during DNA replication [4]. 
The BRCA1 protein, by interactions with tumour suppressor 
proteins (such as P53), cell cycle regulators and DNA repair proteins 
fulfils diverse roles in a variety of DNA repair pathways including 
NHEJ, HR and single strand annealing (SSA). BRCA1 deficient cells 
are characterised by severe patterns of chromosome aberrations and 
extreme genomic instability [5]. BRCA2 on the other hand is primarily 
involved in the process of HR. BRCA2 has been shown to bind to the 
Rad51 recombinase protein which causes strand exchange during the 
process of DSB repair by HR. BRCA2-deficient cells are ineffective in 
recruiting Rad51 to DSB sites and are therefore defective in HR [6].
Mutations in both the BRCA1 and BRCA2 genes have been 
demonstrated to be central to the development of a number of types of 
cancer, in particular breast cancer. While the majority of breast cancers 
are sporadic, germline mutations of the BRCA1 and BRCA2 genes 
are associated with some 5 – 10% of breast cancers where the disease 
is characterised by early onset (usually before the age of 40). Also, 
individuals with such mutations also have an increased susceptibility 
to ovarian, pancreatic, prostatic and male breast cancers [1,7].
A fundamental treatment method for most locally advanced 
cancers, including breast cancer, is clinical fractionated radiotherapy, 
used either as a single modality or in combination with surgery and/or 
chemotherapy [8]. The effectiveness of cancer treatment is frequently 
limited by the development of side effects in the form of normal tissue 
toxicity (NTT). NTT can occur both during treatment (acute response) 
and post-treatment (late response) in a variety of tissues and is 
experienced to a greater or lesser extent by 15 – 20% of all radiotherapy 
patients [8]. Normal tissue reactions have been appreciated for 
well over half a century of clinical radiotherapy practice and have 
been standardised into established scales of NTT for all tissue types 
[9,10]. In addition to the observed standardised scale of NTT, a small 
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Abstract
PARP inhibitors can be used to induce synthetic lethality in cells with bi-allelic BRCA1 and BRCA2 mutations. 
However the effect of PARP inhibitors in combination with radiation on cells with mono-allelic mutations of BRCA1 
and BRCA2 is unknown. We have examined the cell survival response of lymphoblastoid cells derived from normal 
individuals and those derived from carriers of BRCA1 and BRCA2 mutations, following exposure to ionising radiation 
and the PARP inhibitor Olaparib.
Two lymphoblastoid cell lines from normal individuals and three with mono-allelic mutations in BRCA1 and 
BRCA2 were exposed to increasing doses of gamma radiation either alone or in combination with 5 µM Olaparib. 
Cell survival was measured using the MTT assay.
Exposure to increasing doses of gamma radiation caused a reduction in cell survival of all cell types. The 
combined exposure to gamma radiation and 5 µM Olaparib did not enhance cell kill in normal or BRCA2 heterozygote 
lymphoblastoid cells but significantly enhanced cell kill in cells derived from BRCA1 carriers (P = 0.02). The treatment 
of cancer patients carrying mutations in the BRCA1 gene with radiotherapy and the PARP inhibitor Olaparib may 
significantly enhance radiation induced normal tissue toxicity in these patients.
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minority of individuals manifest toxicity reactions that fall outside 
such classifications and these individuals are referred to as ‘over-
reactors’. Individuals with inherited genetic defects in the repair of 
DNA DSB are over-reactors. Classical examples of radiotherapy over-
reactors include individuals with Ataxia Telangiectasia (A-T), where 
an inactivating mutation in the ATM gene results in aberrant cell cycle 
control, defective DNA DSB repair and extreme clinical and cellular 
hypersensitivity to ionising radiation [11]. In addition, we have also 
demonstrated that an inactivating mutation in the DNA-PKcs gene 
(which is central to NHEJ DSB repair), resulted in extreme cellular and 
clinical radiosensitivity eventually leading to the patient’s death as a 
result of radiotherapy-induced neurological trauma [12]. 
Due to the fact that the BRCA1 and BRCA2 proteins are central to 
proficient DNA DSB repair by either NHEJ or HR, it is possible that 
individuals carrying mutations in either of these genes might represent 
a cohort of patients in which radiotherapy-induced NTT might be 
over and above the normal range expected. Indeed cellular clonogenic 
assays in cells derived from BRCA1 and BRCA2 heterozygotes reveal 
elevated radiosensitivity and chromosome aberrations when compared 
to cells derived from normal individuals, which is suggestive of a 
haplo-insufficient phenotype [13]. However, clinical evidence suggests 
that heterozygotes for both BRCA1 and BRCA2 do not experience 
abnormally severe NTT [14]. 
More recently however a novel class of drugs targeted to inhibit 
poly(ADP-ribose) polymerase (PARP) are being investigated for the 
treatment of patients with BRCA1 and BRCA2-negative tumours. 
Several members of the PARP enzyme family have roles in DNA 
repair. However, PARP-1 accounts for approximately 90% of cellular 
PARP activity [15]. PARP-1 is essential for the repair of DNA single 
strand breaks primarily through the mechanism of base excision 
repair, and inhibition of PARP-1 causes the creation of a DNA DSB 
at the site of damage during DNA replication [16]. The first PARP 
inhibitors were nicotinamide analogues such as the benzamides. 
One such compound 3-Aminobenzamide was initially used in the 
clinical setting in combination with cytotoxic chemotherapeutic 
drugs, rather than radiotherapy. Later studies on cell lines from head 
and neck cancer, and from lymphoma, have shown that the PARP 
inhibitor AZD-2281 (Olaparib), when used with ionising radiation, 
produced a synergistic effect [17]. While the use of PARP inhibitors 
for treating patients with BRCA1 and BRCA2 deficient tumours might 
be an effective approach in the clinical management of such cancers, 
the combination of both radiotherapy and PARP inhibition may 
represent a mechanism whereby the effectiveness of radiotherapy may 
be enhanced. The corollary of this approach however, is that patients 
treated with such a combination may experience elevated normal tissue 
toxicity in cells heterozygous for either BRCA1 or BRCA2 mutations. 
To address this question we have examined the cellular sensitivity of 
BRCA1 and BRCA2 heterozygous cells to radiation in the presence 
and absence of the PARP-1 inhibitor Olaparib. We demonstrate that 
B-lymphoblastoid cells heterozygous for BRCA1 show elevated cellular 
sensitivity to radiation in the presence of Olaparib when compared 
to heterozygous BRCA2 B-lymphoblastoids and those from normal 
individuals. We caution that heterozygous BRCA1 patients treated 
with radiotherapy and PARP inhibitors may experience abnormally 
high levels of normal tissue toxicity. 
Materials and Methods
Cell lines
Human B lymphocytes which had been immortalised using the 
Epstein-Barr virus were purchased from Coriell Cell Repositories 
(Camden, New Jersey, USA). Details of the cell lines are shown in Table 
1. Cell lines “BRCA1” and “BRCA2” were heterozygotes for mutations 
in the BRCA1 or BRCA2 genes, respectively.
Cell culture
The cell lines were initially established in T25 cell culture flasks 
(PAA Laboratories Limited, Yeovil, Somerset, UK) in RPMI 1640 
culture medium (Sigma-Aldrich, Poole, Dorset, UK) supplemented 
with 10% foetal bovine serum, 2.0 mM L-Glutamine and 100 Uml−1 
Penicillin and Streptomycin (PAA). Upon reaching 75-80% confluence, 
cell lines were transferred to T75 flasks for further culture. Cells were 
routinely incubated at 37°C in a humidified atmosphere of 5% CO2 in 
air. 
Values for cell concentration (number of cells per ml cell 
suspension) and viability (% live cells/dead cells) were determined as 
required using a “Countess™” automated cell counter based upon the 
method of trypan blue exclusion (Invitrogen, Paisley, Renfrewshire, 
UK). Cell cultures were used over a restricted range of ten passages, 
during which cell viability was not less than 80%. 
MTT assay
Due to the fact that the lymphoblastoid cells used in the study did 
not form colonies in a standard clonogenic assay, the extensively used 
and widely accepted MTT assay was conducted as described previously 
[18,19] using an MTT assay kit (Merck-Millipore Ltd., Watford, UK).
In brief, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) reagent (50 mg) was dissolved in 10 ml PBS (pH 7.4) 
and sterilised by filtration. Ten microlitres of this solution was added 
to each well containing cell suspension on the 96-well microplates, 
and the contents mixed by gentle agitation of the plate, followed by 
incubation for 3 hours (incubation conditions detailed previously). 
Colour development was achieved by the addition of 10 µL propan-2-
ol with 0.04 N HCl and well contents were mixed by retro-pipetting. A 
“BP800” microplate reader (Biohit PLC, Helsinki, Finland) was used to 
obtain absorbance values of each well with a test wavelength of 562 nm 
and a reference wavelength of 630 nm.    
A cell dilution assay was performed to determine the optimum cell 
concentration and volume of cell suspension for use in the MTT assay. 
This was to ensure that the optical density achieved in this assay fell 
within the linear range. It was determined that the optimum values 
were 750 000 cells per ml in a volume of 100 µL cell suspension per 
plate well giving 75 000 cells per plate well. 
Exposure to radiation
The stock cell suspension of each cell line was divided in half and 
each diluted with either complete medium only or a solution of PARP 
inhibitor in complete medium to create two separate cell suspensions 
of concentration 750 000 cells per ml. Each suspension was divided 
into five aliquots in 15 ml centrifuge tubes. One aliquot from each set 
was designated as an un-irradiated control; the remaining four aliquots 
were irradiated with 2, 4, 6 or 8-Gy gamma radiation from a 60Cobalt 
source (Puridec Technologies, Oxfordshire, UK) sited at a distance of 
25 cm with a dose rate between 1.0 and 1.2 Gy per minute.
The un-irradiated and 2, 4, 6, and 8-Gy irradiated cells from both 
the untreated and PARP-inhibitor-exposed (Olaparib) cells were 
seeded using a multi-channel pipette into 96-well microplates in 
quadruplicate (four identical wells). Separate plates were prepared such 
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that independent MTT assays could be performed on each cell line at 
3, 5 and 7 days post-irradiation. The cells were incubated for 3, 5 or 
7 days (incubation conditions detailed previously). Although survival 
was estimated at days 3, 5 and 7, the data shown in the results section 
are derived from a 7 day period following radiation exposure. This was 
chosen to allow maximum time for cell recovery and thus giving an 
accurate reflection of cytoxicity caused by the radiation and Olaparib 
exposure. 
Exposure to the PARP inhibitor Olaparib
To determine the highest non-cytotoxic concentration of Olaparib 
(LC Laboratories Inc, Woburn, Massachusetts, USA) cells were 
exposed to increasing concentrations of the drug in the range of 1.0 
µM to 1000.0 µM (log10 scale). The cells were incubated in the drug 
for 3, 5 and 7 days and survival was determined using the MTT assay. 
The appropriate concentration of Olaparib was found to be 5.0 µM 
following a 7 day exposure; this was the maximum concentration of 
Olaparib that did not cause significant cell death.
Statistical analysis
To compare differences in cell survival after exposure to radiation 
either alone or in combination with Olaparib, a Student’s unpaired 
t-Test was used by comparing the survival of cells after exposure to 2 
Gy gamma radiation (SF2 values). 
Results
Olaparib sensitivity of lymphoblastoid cell lines
The response of the lymphoblastoid cells to increasing 
concentrations of Olaparib is shown in Figure 1. It can be observed 
that increasing the concentration of Olaparib results in a proportionate 
decrease in cell survival of the normal lymphoblastoid cells and 
the BRCA1 and BRCA2 heterozygote cells. There were no marked/
significant differences in response between the three classes of cell line. 
For future experiments it was decided that a concentration of Olaparib 
of 5 µM would be used as a dose which resulted in minimal toxicity to 
all cell lines.
Response of lymphoblastoid cell lines to radiation +/- 
Olaparib
The response of the normal lymphoblastoid cell lines GM00893 and 
GM05423 to 0, 2, 4, 6 and 8 Gy gamma radiation is shown in Figures 
2A and 2B respectively. For each cell line there is a reduction in cell 
survival with increasing dose of gamma radiation. In the GM00893 cell 
line, cell kill is slightly (but not significantly) enhanced in the presence 
of 5 µM Olaparib (Figure 2A). However, for the GM05423 cell lines 
the exposure of cells to Olaparib does not enhance cell kill following 
radiation exposure (Figure 2B). Figure 2C depicts the mean survival of 
the two cell lines plotted as a single graph. 
Three lymphoblastoid cell lines harbouring mono-allelic mutations 
in the BRCA1 gene were examined (GM13705, GM14090 and 
GM16105). The data are shown in Figures 3A-3D. For the GM13705 
lymphoblastoid cells, exposure to increasing doses of gamma radiation 
reduces cell survival and although cell kill is slightly increased by 
the presence of 5 µM Olaparib, this is not a significant enhancement 
(Figure 3A). For the GM14090 and GM16105 cells, we observed a 
significant potentiation of cell kill when the cells were irradiated in the 
presence of 5 µM Olaparib (Figure 3B and 3C). Figure 3D shows the 
response of all cells to radiation when plotted as a single graph. The 
enhancement of radiation induced cell kill by Olaparib is clearly shown 
and is a significant increase in cell kill (p=0.02).
Also the response of three B-lymphoblastoid cell lines with mono-
allelic mutations in the BRCA2 gene to increasing doses of gamma 
radiation in the presence and absence of Olaparib, was investigated and 
the data are shown in Figures 4A-4D. Figure 4A shows the response 
of the GM14170 cells and the data indicate that increasing doses of 
gamma radiation only marginally reduces cell survival in this line and 
moreover, this response is not enhanced by the presence of Olaparib. 
Figure 4B shows the response of the GM14622 cells to gamma radiation. 
Interestingly the cells are significantly more sensitive to the lethal 
effects of gamma radiation than the GM14170 cells shown in Figure 4A 
and moreover, the cytotoxic effect of radiation exposure is enhanced by 
the presence of Olaparib. In Figure 4C, the response of the GM14805 
cells is shown and the data indicates that Olaparib does not enhance 
the cytotoxicity of radiation at any dose examined. In Figure 4D, the 
data derived from the three cell lines is plotted as a single survival curve 
with and without Olaparib exposure. These data show that overall there 
is no significant difference in cell survival of BRCA2 mutation carrier 
cells in the presence or absence of Olaparib. 
To determine if there were significant differences in the response 
of normal lymphoblastoid cells and those derived from BRCA1 and 
BRCA2 mono-allelic cells, the survival of cells following exposure to 
2 Gy gamma radiation (SF2 values) was compared and the data are 
shown in Table 2. Comparison of survival at 2 Gy is particularly 
important because 2 Gy represents a dose of irradiation that induces 
potentially lethal damage (PLD). PLD repair can be affected by 
number parameters such as defects in DNA repair or, in this study, 
the induction of synthetic lethality by PARP inhibition. Two Gray 
irradiation is also an important clinical dose due to the fact that most 
fractionated radiotherapy treatments are given in 2 Gy fractions. By 
comparing the SF2 survival levels of normal and mono-allelic BRCA1 
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Figure 1: shows the survival of normal lymphoblastoid cells and those 
derived from individuals with mono-allelic mutations in the BRCA1 and 
BRCA2 genes. Two normal cell lines are combined to produce the survival 
curve and three are combined to produce the data for the BRCA1 and BRCA2 
cell survival curves. Error bars represent standard error of the mean of at 
least three independent experiments. Due to the logarithmic scale used 
for the Olaparib concentrations (x axis) survival at zero dose is not shown. 
However, survival was 100%. A concentration of 5µM Olaparib was chosen 
for all future experiments as representing concentration with minimal toxicity 
to all cell lines.
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Figures 2: A-C show the response of the two normal lymphoblastoid cell lines to increasing doses of gamma radiation in the presence and absence of 5 µM Olaparib. 
The GM00893 cell line is shown in Figure 2A and the GM05432 cell line is shown in figure 2B. Figure 2C combines two normal cell lines into a single survival curve. 
Broken lines show the response of the cells to gamma radiation alone while the unbroken line shows the response to gamma radiation in the presence of Olaparib. 
Error bars represent standard error of the mean of at least three independent experiments.
 
10
100
0 2 4 6 8
Ce
ll 
Su
rv
iv
al
 (%
)
Radiation Dose (Gy)
GM13705 With Olaparib
GM13705 Without Olaparib
10
100
0 2 4 6 8
Ce
ll 
Su
rv
iv
al
 (%
)
Radiation Dose (Gy)
GM14090 With Olaparib
GM14090 Without Olaparib
10
100
0 2 4 6 8
Ce
ll 
Su
rv
iv
al
 (%
)
Radiation Dose (Gy)
GM16105 With Olaparib
GM16105 Without Olaparib
10
100
0 2 4 6 8
Ce
ll 
Su
rv
iv
al
 (%
)
Radiation Dose (Gy)
BRCA1 Cell Lines With Olaparib
BRCA1 Cell Lines Without Olaparib
A B C D 
Figures 3: A-D show the response of the three lymphoblastoid cell lines with mono-allelic mutations in the BRCA1 gene to increasing doses of gamma radiation in the 
presence and absence of 5 µM Olaparib. The GM13705 cells line is shown in Figure 3A, GM14090 in Figure 3B and GM16105 in Figure 3C. Figure 3D combines the 
three responses into a survival curve. Broken lines show the response of the cells to gamma radiation alone while the unbroken line shows the response to gamma 
radiation in the presence of Olaparib. Error bars represent standard error of the mean of at least three independent experiments.
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Figures 4: A-D show the response of the three lymphoblastoid cell lines with mono-allelic mutations in the BRCA2 gene to increasing doses of gamma radiation in the 
presence and absence of 5 µM Olaparib. The GM14170 cells line is shown in Figure 4A, GM14622 in Figure 4B and GM14805 in Figure 4C. Figure 4D combines the 
three responses into a survival curve. Broken lines show the response of the cells to gamma radiation alone while the unbroken line shows the response to gamma 
radiation in the presence of Olaparib. Error bars represent standard error of the mean of at least three independent experiments.
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cells following exposure increasing doses of gamma radiation, using 
Student’s unpaired T-test, it was seen that there was no significant 
difference in survival (p=0.48). Similarly, by comparing the normal 
lymphoblastoid and mono-allelic BRCA2 cells, there was no significant 
difference in survival after exposure to increasing doses of gamma 
radiation (p=0.227). Also for the normal and BRCA2 mono-allelic 
cells, the survival after radiation exposure was not enhanced with 5 µm 
Olaparib (p=0.934 for normal cells plus and minus Olaparib; p=0.705 
for BRCA2 cells plus and minus Olaparib). However, when BRCA1 
mono-allelic cells were irradiated in the presence of Olaparib, the 
cytotoxicity of gamma radiation was significantly enhanced when the 
SF2 values were compared (p=0.02).
Discussion
The increasing use of PARP inhibitors in the clinical management 
of tumours with bi-allelic mutations in the BRCA1 and BRCA2 genes 
is a novel mechanism of specifically inducing cell kill in the tumour 
cells while theoretically avoiding normal cell damage. The induction 
of cell kill by PARP inhibitors in BRCA1 and BRCA2 cells relies on 
the mechanism of synthetic lethality by inducing two conditions in 
cells that individually would not affect cell survival but together can 
significantly alter a cellular phenotype. In the case of BRCA1 and 
BRCA2 defective cells, the inhibition of PARP-1 and the resultant 
suppression of base excision repair results in the conversion of DNA 
single strand break to DNA DSB which results in the collapse of DNA 
replication forks leading to cell death. There is significant experimental 
and clinical evidence that PARP inhibition results in increased tumour 
cell death [20]. In addition, clinical and experimental evidence suggests 
that PARP inhibition does not affect the survival of cells with mono-
allelic mutations of BRCA1 and BRCA2. However, the combination 
of the use of PARP inhibitors with other forms of cytotoxic cancer 
treatment may cause significant toxicity in cells with a mono-allelic 
mutation of either of these genes.
In this study we conducted an in vitro study to determine if cells 
heterozygous for BRCA1 and BRCA2 mutation would display elevated 
sensitivity to radiation when treated in the presence of the PARP-1 
inhibitor Olaparib. While lymphoblastoid cells from normal individuals 
and those carrying a mono-allelic mutation in the BRCA2 gene did not 
display elevated radiosensitivity, the three lymphoblastoid cell lines 
with mono-allelic mutations in the BRCA1 gene exhibited a significant 
reduction in cell survival after radiation exposure in combination with 
PARP-1 inhibition by Olaparib. 
Individual differences in cell line sensitivity may in part account for 
the observed differences in sensitivity between the groups of cell lines. 
However when the individual cell line data is combined and plotted 
as a single graph as in Figure 3D and 4D it was clear that there were 
significant differences between BRCA1 and BRCA2 mutation carriers. 
(Response to reviewer 1 point 1 and 2). Therefore these observations 
suggest that a haplo-insufficient phenotype can be exposed in BRCA1 
carrier cells when the combination PARP inhibition and radiation 
is used to kill cells. As a result this observation may have significant 
clinical implications.
Since the use of radiotherapy for the treatment of cancer, a 
significant limitation in its use for the treatment of all cancer types 
is the phenomenon of normal tissue toxicity. NTT is experienced by 
some 15–20% of all radiotherapy patients to a greater or lesser degree 
and moreover, normal fractionated clinical radiotherapy has the 
potential to be fatal in those individuals with inherited defects in DNA 
DSB repair mechanisms such as A-T [11]. Thus the clinical application 
of a strategy to inhibit a DNA repair process prior to radiotherapy (in 
this case the inhibition of base excision repair by PARP-1 suppression) 
in patients carrying BRCA1 mutations may increase the number of 
patients experiencing NTT.
The reasons as to why this enhancement of sensitivity is observed 
only in the BRCA1 heterozygote cells is interesting and may be due 
to a number of factors. Firstly the specific nature of the mono-allelic 
mutation in the BRCA1 and BRCA2 cell lines may confer differential 
levels of functional protein in each cell line thus influencing the 
response to radiation and the PARP-1 inhibitor Olaparib. By examining 
Cell Line Type Details of BRCA Gene Mutation
GM00893 Normal None
GM05423 Normal None
GM13705 BRCA1 4-base pair deletion in exon 11 = truncated protein. 
GM14090 BRCA1 2-base pair deletion in exon 3 = truncated protein.
GM16105 BRCA1 Base substitution in intron 8.
GM14170 BRCA2 1-base pair deletion in exon 11 = frameshift mutation.
GM14622 BRCA2 2-base pair deletion in exon 11 = frameshift mutation = truncated protein.
GM14805 BRCA2 Base substitution in exon 7 = nonsense mutation.
Table 1 provides a description of the B-Lymphoblastoid cell lines used in the study together with the information on the mono-allelic mutation in the BRCA1 and BRCA2 
heterozygous cell lines
Table 1: Description of B-Lymphoblastoid cell lines used in study.
Table 2 shows the surviving fraction following exposure to 2 Gy gamma radiation (SF2). For each cell line the data are derived from a minimum of three independent 
experiments. The means SF2 for each cell lines with or without incubation with 5 µM Olaparib is shown together with the standard error of the mean SF2. Statistical analysis 
using a Student’s unpaired T-test show that there are no significant differences in the SF2 values when the normal lymphoblastoid cells are compared with either the 
BRCA1 and BRCA2 heterozygous cells. However, BRCA1 heterozygous cells are significantly more sensitive to ionising radiation in the presence of the PARP-1 inhibitor 
Olaparib (P =0.02)
Table 2: Surviving fraction at 2 Gray (SF2) of each cell line irradiated with gamma radiation. 
 
CELL LINE
NORMAL BRCA1 BRCA2
GM00893 GM05423 GM13705 GM14090 GM16105 GM14170 GM14622 GM14805
Olaparib  +  -   +  -    +  -  +  -  +  -  +  -  +  -  + - 
SF2 Mean (%) 83.2 89.5 86.9 82.3 75.3 84.1 78.1 89.4 43.5 69.3 79.1 82.7 49.3 70.5 87.1 79
SF2 Standard Error 10.6 7.5 7.1 15 7.3 8.2 2.2 2.2 1.4 3.1 4.0 11.0 8.2 10.0 6.5 5.1
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the mutation in each of the three BRCA1 and three BRCA2 cell lines in 
Table 1, it shows that of the three BRCA1 cell lines two contain deletions 
resulting in truncated proteins and one has an intron 8 mutation 
presumably affecting RNA splicing. Thus it is unlikely that these alleles 
are capable of producing a functional protein. A similar analysis with 
the BRCA2 cell lines reveal two with deleterious frameshift mutations 
and one with a mutation leading to the introduction of a nonsense 
codon. Again it is unlikely that these alleles are functional. Therefore it 
is probable that similar levels of protein are being produced in the cell 
lines and other factors are likely to be responsible for this interesting 
phenotype.
Another factor which may underpin the specific BRCA1 phenotype 
observed in this study is related to the differential function of the BRCA1 
and BRCA2 proteins. BRCA1 has an important role in NHEJ, HR, SSA 
and is known to interact with tumour suppressor genes (such as P53) 
and other cell cycle regulators. Therefore a mono-allelic mutation of 
BRCA1 might lead to haplo-insufficient phenotypes in DNA repair 
when PARP-1 is inhibited increasing the number of DNA double 
strand breaks. However, the effect of PARP-1 inhibition on a BRCA2 
heterozygote cell might be more tolerable. This is because the role of 
BRCA2 protein is specific to the process of HR where it is involved in 
loading Rad51 recombinase at the sites of DNA DSB. Therefore, DNA 
repair processes such as NHEJ are likely still fully functional in these 
cells and can effectively “mop up” additional DNA DSB induced by 
PARP-1 inhibition.
In conclusion this fundamental study of radiation sensitivity in a 
collection of B-lymphoblastoid cells has revealed potentially important 
clinical issues. Firstly, in patients with monoallelic mutations in either 
BRCA1 or BRCA2 are unlikely to experience abnormally high levels 
of NTT during or after radiotherapy. Secondly we observe a haplo-
insufficient phenotype in cells with mono-allelic mutations of the 
BRCA1 gene when radiotherapy is combined with PARP-1 inhibition 
by Olaparib. While this observation requires further validation with a 
larger number of cells lines, the data reveal tantalising evidence that 
the clinical application of PARP inhibitors used concomitantly with 
radiotherapy may increase the number of individuals that experience 
radiation induced NTT. 
Acknowledgments
Dr. Emma Bourton was supported by a grant from the Vidal Sassoon 
Foundation of America. This research was also supported in part by a grant from 
“The Balls to Cancer” Charity, Coventry, UK.
References
1. Yoshida K, Miki Y (2004) Role of BRCA1 and BRCA2 as regulators of DNA 
repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 
95: 866-871.
2. Venkitaraman AR (2001) Functions of BRCA1 and BRCA2 in the biological 
response to DNA damage. J Cell Sci 114: 3591-3598.
3. Burma S, Chen BP, Chen DJ (2006) Role of non-homologous end joining 
(NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 5: 1042-1048.
4. Scott SP, Pandita TK (2006) The cellular control of DNA double-strand breaks. 
J Cell Biochem 99: 1463-1475.
5. Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a 
common pathway of genome protection. Nat Rev Cancer 12: 68-78.
6. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH (2009) Structural basis for 
recruitment of BRCA2 by PALB2. EMBO Rep 10: 990-996.
7. Kote-Jarai Z, Eeles RA (1999) BRCA1, BRCA2 and their possible function in 
DNA damage response. Br J Cancer 81: 1099-1102.
8. Lawrence TS, Ten Haken RK, Giaccia A (2008) Principles of Radiation 
Oncology. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer: 
Principles and Practice of Oncology, (8th edn). Philadelphia: Lippincott Williams 
and Wilkins 307-336. 
9. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy 
Oncology Group (RTOG) and the European Organization for Research and 
Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31: 1341-1346.
10. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, et al. (2003) CTCAE v3.0: 
development of a comprehensive grading system for the adverse effects of 
cancer treatment. Semin Radiat Oncol 13: 176-181.
11. Lavin MF, Shiloh Y (1997) The genetic defect in ataxia-telangiectasia. Annu 
Rev Immunol 15: 177-202.
12. Abbaszadeh F, Clingen PH, Arlett CF, Plowman PN, Bourton EC, et al. (2010) 
A novel splice variant of the DNA-PKcs gene is associated with clinical and 
cellular radiosensitivity in a patient with xeroderma pigmentosum. J Med Genet 
47: 176-181.
13. Buchholz TA, Wu X, Hussain A, Tucker SL, Mills GB, et al (2002) Evidence 
of haplotype insufficiency in human cells containing a germline mutation on 
BRCA1 or BRCA2. International Journal of Cancer 97: 557-561. 
14. Leong T, Whitty J, Keilar M, Mifsud S, Ramsay J, et al. (2000) Mutation analysis 
of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive 
cancer patients. Int J Radiat Oncol Biol Phys 48: 959-965.
15. Davar D, Beumer JH, Hamieh L, Tawbi H (2012) Role of PARP inhibitors in 
cancer biology and therapy. Curr Med Chem 19: 3907-3921.
16. McGlynn P, Lloyd RG (2002) Recombinational repair and restart of damaged 
replication forks. Nat Rev Mol Cell Biol 3: 859-870.
17. Plummer ER (2006) Inhibition of poly(ADP-ribose) polymerase in cancer. Curr 
Opin Pharmacol 6: 364-368.
18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: 
application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-
63.
19. Green LM, Reade JL, Ware CF (1984) Rapid colorimetric assay for cell viability: 
application to the quantitation of cytotoxic and growth inhibitory lymphokines. J 
Immunol Methods 70: 257-268.
20. Weil MK, Chen AP (2011) PARP inhibitor treatment in ovarian and breast 
cancer. Curr Probl Cancer 35: 7-50.
Citation: Bourton EC, Foster HA, Plowman PN, Harvey AJ, Parris CN 
(2013) Hypersensitivity of BRCA1 Heterozygote Lymphoblastoid Cells to 
Gamma Radiation and PARP Inhibitors. J Genet Syndr Gene Ther 4: 146. 
doi:10.4172/2157-7412.1000146
This article was originally published in a special issue, Cancer Genetics 
handled by Editor(s). Dr. Ahmed M Malki,  Alexandria University, Egypt
